Delcath Systems, Inc.  

(Public, NASDAQ:DCTH)   Watch this stock  
Find more results for DCTH
-0.008 (-2.50%)
After Hours: 0.313 0.000 (0.00%)
Jan 23, 5:56PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.31 - 0.34
52 week 0.30 - 7.20
Open 0.33
Vol / Avg. 1.66M/1.77M
Mkt cap 707,033.00
P/E     -
Div/yield     -
EPS -10.07
Shares 2.20M
Beta 2.20
Inst. own 17%
Mar 20, 2017
Q4 2016 Delcath Systems Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Dec 7, 2016
Delcath Systems Inc at LD Micro Main Event
Nov 11, 2016
Q3 2016 Delcath Systems Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -231.03% -841.67%
Operating margin -1085.98% -870.64%
EBITD margin - -835.32%
Return on average assets -10.29% -74.46%
Return on average equity -81.30% -109.95%
Employees 35 -
CDP Score - -


1633 Broadway Ste 22C
NEW YORK, NY 10019-6708
United States - Map
+1-212-4892100 (Phone)
+1-212-4892102 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Officers and directors

Roger G. Stoll Ph.D. Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Jennifer K. Simpson Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Barbra C. Keck Principal Financial Officer, Senior Vice President - Finance, Principal Accounting Officer, Secretary
Age: 37
Bio & Compensation  - Reuters
John Purpura Executive Vice President - Regulatory Affairs and Quality Assurance
Age: 53
Bio & Compensation  - Reuters
Harold S. Koplewicz M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
William Dodge Rueckert Independent Director
Age: 62
Bio & Compensation  - Reuters
Marco Taglietti M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters